Inflammatory bowel syndrome

Reading File

Finding Sources

Searching PubMed

"inflammatory bowel disease"[MeSH Terms] AND "management"[MeSH Terms]

Reading File

Searching PubMed

"inflammatory bowel disease" AND "therapy"

Reading File

I now have comprehensive content from multiple authoritative sources. I can also note the user wrote "Inflammatory bowel syndrome" - which is a mix of IBD (Inflammatory Bowel Disease) and IBS (Irritable Bowel Syndrome). I'll cover both clearly, since this is a common confusion. Let me now compile the full answer.

Note: You wrote "Inflammatory Bowel Syndrome" - this is likely a blend of two distinct conditions: Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). They are often confused but are fundamentally different. I'll cover both comprehensively below.

Inflammatory Bowel Disease (IBD)

Overview

IBD is a chronic, immune-mediated inflammatory condition of the gastrointestinal tract. It encompasses two major diseases - Ulcerative Colitis (UC) and Crohn's Disease (CD) - plus a third, less common entity, microscopic colitis.

Incidence: 1.5-8 new cases per 100,000 U.S. population per year
More common in whites; no strong gender predominance (slight male predominance in Crohn's, female in UC)
Bimodal age of onset: peak at ages 15-25, second peak at 55-65 years
Affects approximately 500,000 Americans; worldwide prevalence continues to rise

(Textbook of Family Medicine 9e, p. 1140)

Ulcerative Colitis (UC)

Pathology

UC involves only the mucosal layer of the colon, always starting in the rectum and extending proximally in a continuous, symmetric pattern:

Proctitis - limited to rectum
Proctosigmoiditis - rectum + sigmoid
Left-sided colitis - distal to splenic flexure
Pancolitis - entire colon; can cause backwash ileitis via patent ileocecal valve

Hallmarks on colonoscopy: confluent erythematous inflammation, friability, pseudopolyp formation in chronic disease.

Symptoms

Mild-to-moderate: diarrhea (often bloody), urgency, tenesmus
Severe/fulminant: fever, fatigue, dehydration, weight loss, acute abdomen
Rare but life-threatening: toxic megacolon

Crohn's Disease (CD)

Pathology

Crohn's can involve any part of the GI tract from mouth to anus, including the biliary tree. Key distinguishing features:

Transmural inflammation (full thickness of bowel wall)
Discontinuous "skip lesions" - asymmetric, patchy involvement
Most common site: terminal ileum (immunologically rich)
Rectum involved in <50% of cases (vs. always in UC)
Complications: abscesses, perianal fistulas, strictures, bowel obstruction
Cobblestone mucosa, aphthous ulcers, rake-like lesions on colonoscopy

Symptoms

Vague abdominal pain (may be mild), intermittent diarrhea
Postprandial crampy pain suggesting small bowel obstruction
Perianal disease: fistulas, abscesses, sinus tracts (pathognomonic for Crohn's, not UC)

(Textbook of Family Medicine 9e, p. 1141; Sleisenger & Fordtran's GI & Liver Disease)

Extraintestinal Manifestations (Both UC and CD)

These can be the presenting symptoms and may flare with intestinal disease:

System	Manifestation
Eyes	Uveitis, iritis, episcleritis
Joints	Large-joint arthritis, sacroiliitis (enteropathic arthritis)
Skin	Erythema nodosum, pyoderma gangrenosum, perianal fistulas
Liver	Primary sclerosing cholangitis (especially UC)

Etiology & Genetics

Genetic factors play a major role. First-degree relatives of IBD patients carry an almost 10% lifetime risk of developing the disease, often mirroring the family member's disease type and course. The pathogenesis involves dysregulated immune responses to intestinal flora in genetically susceptible individuals.

Diagnosis

Colonoscopy with biopsy - gold standard; must include ileal intubation with biopsies of both normal and abnormal mucosa
Labs: CBC (anemia, leukocytosis), ESR, CRP, fecal calprotectin
Imaging: CT/MRI enterography for small bowel involvement
Stool cultures to exclude infectious colitis

Treatment of IBD

Induction of Remission

Drug	Use	Notes
Systemic corticosteroids	Both UC and CD flares	Remission rate ~70% in CD vs. 30% placebo; NOT for maintenance
Budesonide	CD and distal UC flares	Nonsystemic steroid; fewer side effects
5-ASA (sulfasalazine, mesalamine)	Mild UC (induction + maintenance)	Largely ineffective in CD
Azathioprine / 6-mercaptopurine	CD (slow-acting, remission + maintenance)	Add to steroids; help with steroid tapering
Methotrexate	CD remission induction	Monitor CBC and liver enzymes monthly; avoid in pregnancy
Infliximab (anti-TNF-α)	Steroid-resistant CD (~60% effective)	Risks: TB reactivation, infusion reactions, worsening heart failure, invasive fungal infections

Key principle: Steroids induce but do NOT maintain remission. Maintenance requires 5-ASA (UC), immunomodulators, or biologics.

(Textbook of Family Medicine 9e, p. 1142-1143)

Advanced Therapies (2024 Update)

A 2024 AGA Network Meta-Analysis (Ananthakrishnan et al., Gastroenterology 2024) compared advanced therapies for moderate-to-severe UC, evaluating biologics including vedolizumab, ustekinumab, and JAK inhibitors (tofacitinib, upadacitinib). This is now the reference synthesis for treatment selection in refractory disease.

Colorectal Cancer (CRC) Risk in IBD

IBD is a significant CRC risk factor - surveillance colonoscopy is mandatory:

UC: CRC risk begins after 7 years of disease, rises ~10% per decade, reaching up to 34% at 30 years in some tertiary-center studies (population-based studies suggest 15-18% at 30 years)
Risk correlates with duration and extent of disease; universal colitis carries greatest risk
Proctitis-only carries only minimally increased risk vs. general population
Crohn's disease: CRC risk 4-20x the general population; mucinous carcinomas common in bypassed/strictured segments
Dysplasia (low-grade to high-grade) is the recognized precursor to CRC in IBD

(Sleisenger & Fordtran's Gastrointestinal and Liver Disease, p. 2617)

Irritable Bowel Syndrome (IBS)

Overview

IBS is a functional bowel disorder - there is no structural or biochemical abnormality. It is characterized by:

Chronic/recurrent abdominal pain
Altered stool form and/or frequency (diarrhea and/or constipation)
Bloating/distention
Global prevalence (Rome IV criteria): 4.1%; more common in women (5.2%) than men (2.9%)
In the US/UK/Canada: ~4.6% prevalence
~4.4 million annual physician visits
Costs >$20 billion annually in the US

(Goldman-Cecil Medicine, International Edition)

Subtypes (Rome IV)

Subtype	Frequency
IBS-D (predominant diarrhea)	35-40%
IBS-M (mixed bowel habits)	35-40%
IBS-C (predominant constipation)	~25%
IBS-U (unclassified)	<5%

Subtypes can transition over time in the same patient.

Diagnosis: Rome IV Criteria

Recurrent abdominal pain, on average at least 1 day/week in the last 3 months, associated with 2 or more of:

Related to defecation
Associated with a change in stool frequency
Associated with a change in stool form/appearance

Symptoms present for at least 6 months.

(The earlier Rome III criteria required symptoms on ≥3 days of ≥3 months with ≥6 months' duration.)

Pathophysiology

IBS is multifactorial, resulting from dysregulation of gut-brain interactions:

Visceral hypersensitivity - enhanced afferent signaling from gut to CNS
Altered intestinal motility (slower in IBS-C, faster in IBS-D)
CNS modulation abnormalities
Gut microbiota dysbiosis
Mucosal immune activation
Psychological factors: anxiety, somatoform disorders, history of trauma found in 42-61% of GI-referred IBS patients

Risk factors: genetic predisposition, adverse childhood experiences, post-infectious gastroenteritis, food triggers, and stress.

Key Distinction: IBD vs. IBS

Feature	IBD	IBS
Structural damage	Yes (inflammation, ulceration)	No
Bleeding	Common	Rare/absent
Nocturnal symptoms	Common	Uncommon
Biomarkers	CRP, ESR, fecal calprotectin elevated	Normal
Colonoscopy	Abnormal	Normal
Weight loss	Common in active disease	Uncommon

Clinical pitfall: IBS is far more prevalent than IBD. A major diagnostic error is mislabeling IBD patients as having IBS. Mucus in the stool is nonspecific and occurs in both conditions.

Treatment of IBS

Treatment is directed at the predominant symptom:

Lifestyle/Dietary:

Low-FODMAP diet (fermentable oligosaccharides, disaccharides, monosaccharides, polyols)
Soluble fiber supplementation (IBS-C)
Avoidance of food triggers

Pharmacological:

IBS-C: Osmotic laxatives, lubiprostone, linaclotide, plecanatide
IBS-D: Loperamide, rifaximin (non-absorbable antibiotic), alosetron (severe IBS-D in women)
Abdominal pain: Antispasmodics (dicyclomine, hyoscine), low-dose tricyclic antidepressants (amitriptyline), SNRIs
Bloating: Rifaximin, simethicone, peppermint oil

Psychological therapies:

Cognitive-behavioral therapy (CBT), gut-directed hypnotherapy, and mindfulness are effective, especially in patients with comorbid anxiety/depression

Summary

IBD (UC and Crohn's) = organic disease with structural inflammation, requiring long-term immunosuppression and cancer surveillance
IBS = functional gut-brain disorder, diagnosed by exclusion using Rome IV criteria, managed symptomatically
Both are chronic conditions with significant impact on quality of life and healthcare resource use

Sources:

Textbook of Family Medicine 9e, pp. 1140-1143
Sleisenger and Fordtran's Gastrointestinal and Liver Disease, pp. 1966, 2617
Goldman-Cecil Medicine (International Edition), Chapter 16
AGA 2024 Network Meta-Analysis on advanced UC therapies (Ananthakrishnan et al., Gastroenterology, 2024, PMID 39425738)

This is a shared conversation. Sign in to Orris to start your own chat.